Scheler on shame: a critical review

This paper presents a critical review of Scheler’s analysis of shame's structure, dynamic, and affectivity, and his explanation of phenomena of shame. This first part of the paper examines Scheler’s accounts of shame’s basic condition, the law ultimately governing its origin, and its basic dynamic. The second part of the paper turns to his general descriptions of what we feel when we feel shame and his analyses of two distinct forms of shame. The conclusion attempts to draw these aspects of his account of shame together to illustrate why, according to Scheler, we feel shame. Throughout the paper, some basic criticisms of Scheler’s account are advanced. At the same time the paper attempts to demonstrate the virtues of his highly differentiated descriptions of experiences of shame and his attempt to weave these descriptions together into a general theory.Published versio

A crítica de Scheler à ontologia fundamental de Heidegger

O presente texto foi originalmente publicado em uma coletânea sobre Max Scheler, intitulada Max Schelr´s Acting Persons, no ano de 2002. O nome do volume, cuja tradução seria algo como A pessoa atuante de Max Scheler, é provavelmente uma referência ao livro de Karol Wojtyla, mais conhecido como Papa João Paulo II, cujo livro publicado em polonês teria como título traduzido em inglês The acting Person e cujo debate antropo-filosófico tem como ponto de partida as críticas de Scheler a Kant. O leitor do presente texto encontrará em suas linhas um pouco da crítica que este fenomenólogo fez a Ser e Tempo, tratado filosófico de Martin Heidegger publicado em 1927. Max Scheler, que veio a morrer em 1928, deixou em suas anotações as suas críticas ao tratado. O autor do presente texto, o professor da Boston University Daniel O. Dahlstrom, percorre a crítica de Scheler a partir sobretudo da filosofia da religião scheleriana – mas não somente-, marcadamente católica, cujo embate com a filosofia de Heidegger se daria pelo flagrante calvinismo desta. Surpreendentes perspectivas que estão filosoficamente traduzidas e dispostas nas páginas que se seguem

Mesopontine rostromedial tegmental nucleus neurons projecting to the dorsal raphe and pedunculopontine tegmental nucleus: psychostimulant-elicited Fos expression and collateralization

The mesopontine rostromedial tegmental nucleus (RMTg) is a GABAergic structure in the ventral midbrain and rostral pons that, when activated, inhibits dopaminergic neurons in the ventral tegmental area and substantia nigra compacta. Additional strong outputs from the RMTg to the pedunculopontine tegmental nucleus pars dissipata, dorsal raphe nucleus, and the pontomedullary gigantocellular reticular formation were identified by anterograde tracing. RMTg neurons projecting to the ventral tegmental area express the immediate early gene Fos upon psychostimulant administration. The present study was undertaken to determine if neurons in the RMTg that project to the additional structures listed above also express Fos upon psychostimulant administration and, if so, whether single neurons in the RMTg project to more than one of these structures. We found that about 50% of RMTg neurons exhibiting retrograde labeling after injections of retrograde tracer in the dorsal raphe or pars dissipata of the pedunculopontine tegmental nucleus express Fos after acute methamphetamine exposure. Also, we observed that a significant number of RMTg neurons project both to the ventral tegmental area and one of these structures. In contrast, methamphetamine-elicited Fos expression was not observed in RMTg neurons labeled with retrograde tracer following injections into the pontomedullary reticular formation. The findings suggest that the RMTg is an integrative modulator of multiple rostrally projecting structures

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe